-
公开(公告)号：US11512142B2
公开(公告)日：2022-11-29
申请号：US16864570
申请日：2020-05-01
发明人： Zhu Chen , Kenneth Ellsworth , James Milligan , Elizabeth Oldham , Dietmar Seiffert , Bianka Prinz
IPC分类号： C07K16/36 , A61K39/395 , A61K39/00
摘要： Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
-
公开(公告)号：US20220267370A1
公开(公告)日：2022-08-25
申请号：US17617782
申请日：2020-06-22
摘要： A method that uses Protein A chromatography to separate antigen-binding polypeptide monomers comprising one or more immunoglobulin single variable domains (ISVDs) from aggregates of said monomers is disclosed.
-
公开(公告)号：US11413292B2
公开(公告)日：2022-08-16
申请号：US16966961
申请日：2019-02-11
IPC分类号： A61K31/53 , A61K31/427 , A61K31/4418 , A61K31/505 , A61K31/513 , A61K31/52 , A61K31/5365 , A61K31/635 , A61K31/675 , A61K31/7068 , C07D471/18 , C07D498/18
摘要： The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R1 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
-
公开(公告)号：US20220235312A1
公开(公告)日：2022-07-28
申请号：US17396727
申请日：2021-08-08
发明人： Michael Wayne Vandiver , Eva Fan Gefroh , Rebecca Eileen McCoy , Robert James Piper, JR. , Mark A. Brower , Nuno J. Dos Santos Pinto , William N. Napoli , Rachel Y. Straughn , Lisa A. Connell-Crowley , Megan J. McClure
摘要： Disclosed are a process and an automated facility for manufacturing a purified protein of interest. The protein of interest can be a recombinant or naturally occurring protein and/or a therapeutic or other medically useful protein. For example, the disclosed process and automated facility are useful for manufacturing a purified protein drug substance.
-
公开(公告)号：US20220235311A1
公开(公告)日：2022-07-28
申请号：US17396725
申请日：2021-08-08
发明人： Michael Wayne Vandiver , Eva Fan Gefroh , Rebecca Eileen McCoy , Robert James Piper, JR. , Mark A. Brower , Nuno J. Dos Santos Pinto , William N. Napoli , Rachel Y. Straughn , Lisa A. Connell-Crowley , Megan J. McClure
摘要： Disclosed are a process and an automated facility for manufacturing a purified protein of interest. The protein of interest can be a recombinant or naturally occurring protein and/or a therapeutic or other medically useful protein. For example, the disclosed process and automated facility are useful for manufacturing a purified protein drug substance.
-
公开(公告)号：US20220235041A1
公开(公告)日：2022-07-28
申请号：US17619338
申请日：2020-06-02
申请人： Brendan M. CROWLEY , Philippe NANTERMET , David OLSEN , Takao SUZUKI , Merck Sharp & Dohme Corp.
IPC分类号： C07D413/14 , C07D413/12 , C07D417/10 , A61K31/422 , A61K31/541 , C07D471/04 , A61K31/437 , C07D413/10 , A61K45/06 , A61P31/06 , A61P31/08
摘要： Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole compounds, methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of these dihydroisoxazole compounds and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
-
公开(公告)号：US20220233647A1
公开(公告)日：2022-07-28
申请号：US17614680
申请日：2020-06-01
发明人： Danqing Feng , Songnian Lin , Dmitri A. Pissarnitski , Brenda Pipik , Lin Yan , Yuping Zhu
摘要： Glucose-responsive insulin conjugates that contain one or more linear oligomer sugar cluster are provided. Such insulin conjugates that may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.
-
公开(公告)号：US20220228184A1
公开(公告)日：2022-07-21
申请号：US17257792
申请日：2019-07-02
发明人： Mark A. Huffman , Anna Fryszkowska , Joshua N. Kolev , Paul N. Devine , Kevin R. Campos , Matthew Truppo , Christopher C. Nawrat
摘要： The present invention relates to an enzymatic synthesis of 4′-ethynyl-2′-deoxy nucleosides and analogs thereof, for example EFdA, that eliminates the use of protecting groups on the intermediates, improves the stereoselectivity of glycosylation and reduces the number of process steps needed to make said compounds. It also relates to the novel intermediates employed in the process.
-
公开(公告)号：US20220220117A1
公开(公告)日：2022-07-14
申请号：US17657515
申请日：2022-03-31
发明人： Matthew A. Larsen , Amjad Ali , Jared Cumming , Duane DeMong , Qiaolin Deng , Thomas H. Graham , Elisabeth Hennessy , Andrew J. Hoover , Ping Liu , Kun Liu , Umar Faruk Mansoor , Jianping Pan , Christopher W. Plummer , Aaron Sather , Uma Swaminathan , Huijun Wang , Yonglian Zhang
IPC分类号： C07D487/04
摘要： In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
-
20.发明授权公开(公告)号：US11377693B2
公开(公告)日：2022-07-05
申请号：US15533769
申请日：2015-12-08
申请人： Mark D. Ayers , Andrey Loboda , Jared K. Lunceford , Terrill K. McClanahan , Erin E. Murphy , Michael Nebozhyn , Merck Sharp & Dohme Corp.
发明人： Mark D. Ayers , Andrey Loboda , Jared K. Lunceford , Terrill K. McClanahan , Erin E. Murphy , Michael Nebozhyn
IPC分类号： C12Q1/6886 , G16B20/00 , G16B30/00 , G16B40/00 , C07K16/28 , C12Q1/68 , G16B40/30 , G16B20/20 , G16H50/30 , A61K39/00
摘要： A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
5165 条记录 (耗时 0.038 秒)
